<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945724</url>
  </required_header>
  <id_info>
    <org_study_id>IELSG30</org_study_id>
    <secondary_id>EudraCT Number 2009-011789-26</secondary_id>
    <nct_id>NCT00945724</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis</brief_title>
  <acronym>IELSG30</acronym>
  <official_title>A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Extranodal Lymphoma Study Group (IELSG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Extranodal Lymphoma Study Group (IELSG)</source>
  <brief_summary>
    <textblock>
      This trial is a phase II non-comparative study aimed to determine the feasibility and
      toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and
      systemic intermediate-dose methotrexate followed by loco-regional radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events assessments</measure>
    <time_frame>throughout the active treatment period until 30 days after the last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activity of the drugs</measure>
    <time_frame>After the 3rd course (and before the 4th) of R-CHOP. Clinical response will be re-assessed at the end of planned treatment, one-two month after the completion of the whole therapy, including radiotherapy In the follow up period every 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Large B-cell Diffuse Lymphoma of Testis</condition>
  <arm_group>
    <arm_group_label>R-CHOP, Depocyte, Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate</intervention_name>
    <description>Weeks 1-15:
6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days
Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle
IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4&amp;5 of R-CHOP
Weeks 18-22:
• Methotrexate 1.5 g/m2 q14 Days x 2
From Week 24:
• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)</description>
    <arm_group_label>R-CHOP, Depocyte, Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with primary testicular lymphoma at diagnosis. Histological subtype included
             into the study is only Diffuse Large B Cell Lymphoma (Attachment 2: WHO classification
             of lymphoma).

          2. Orchiectomy is mandatory, before enrolment of the patient into the study.

          3. Orchiectomy should be performed within 2 months before study entry.

          4. Age 18-80

          5. Untreated patients

          6. Ann Arbor Stage IE and IIE. Bilateral testicular involvement at presentation will not
             be considered Stage IV. These patients may be included into the study and the final
             Ann Arbor stage (I or II) will be determined by the extent of nodal disease.

          7. Bidimensionally measurable or evaluable disease. Patients who have had all disease
             removed by surgery are eligible.

          8. Adequate haematological counts: ANC &gt; 1.0 x 109/L and PLTs count &gt; 75 x 109/L

          9. Cardiac ejection fraction ≥ 45% by MUGA scan or echocardiography

         10. Non peripheral neuropathy or any active non-neoplastic CNS disease.

         11. No other major life-threatening illnesses that may preclude chemotherapy

         12. Conjugated bilirubin ≤ 2 x ULN.

         13. Alkaline phosphatase and transaminases ≤ 2 x ULN.

         14. Creatinine clearances ≥ 45 ml/min.

         15. HIV negativity

         16. HBV negativity or patients with HBVcAb +, HbsAg -, HBs Ab+/- with HBV-DNA negative

         17. HCV negativity with the exception of patients with no signs of active chronic
             hepatitis histologically confirmed

         18. Life expectancy &gt; 6 months.

         19. Performance status &lt; 2 according to ECOG scale.

         20. No psychiatric illness that precludes understanding concepts of the trial or signing
             informed consent

         21. Written informed Consent

        Exclusion Criteria:

          1. Has known or suspected hypersensitivity or intolerance to rituximab

          2. History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances

          3. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable
             dose for at least 3 months before first dose of study drug)

          4. Uncontrolled or severe cardiovascular disease including myocardial infarction within 6
             months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure
             (Attachment 5, NYHA Classification of Cardiac Disease), uncontrolled angina,
             clinically significant pericardial disease, or cardiac amyloidosis

          5. History of clinically relevant hypotension

          6. CNS involvement (meningeal and/or brain involvement by lymphoma)

          7. Evolving malignancy within 3 years with the exception of localized non-melanomatous
             skin cancer

          8. HIV positivity

          9. HBV positivity with the exception of patients with HBVcAb +, HbsAg -, HBs Ab+/- with
             HBV-DNA negative

         10. HCV positivity with the exception of patients with no signs of active chronic
             hepatitis histologically confirmed

         11. Active opportunistic infection

         12. Receipt of extensive radiation therapy, systemic chemotherapy, or other antineoplastic
             therapy

         13. Exposure to Rituximab prior study entry

         14. Have received an experimental drug or used an experimental medical device within 4
             weeks before the planned start of treatment. Concurrent participation in non-treatment
             studies is allowed, if it will not interfere with participation in this study.

         15. Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuele Zucca, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IOSI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuele Zucca, MD</last_name>
    <phone>++41918119040</phone>
    <email>ielsg@eoc.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppina Cabras, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S. Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele H Scientific Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Ferreri, MD</last_name>
      <email>ferreri.andres@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andrés JM Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia AUSL Ravenna</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IFO Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Pisani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Avvisati, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università La Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Balzarotti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Giovanni Battista-Molinette, S.C. Ematologia 2</name>
      <address>
        <city>Torino</city>
        <zip>10134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Vitolo, M.D.</last_name>
      <email>uvitolo@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Umberto Vitolo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graziella Pinotti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IOSI</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Zucca, MD</last_name>
      <phone>+41 91 8119040</phone>
      <email>ielsg@ticino.com</email>
    </contact>
    <investigator>
      <last_name>Emanuele Zucca, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

